021-51111890
购物车（）
sales@molnova.cn
Etalocib
CAS No. 161172-51-6
Etalocib ( LY293111; VML295 )
产品货号. M23713 CAS No. 161172-51-6
Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase.
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 5MG | ￥2811 | 有现货 |
|
| 10MG | ￥4560 | 有现货 |
|
| 25MG | ￥7209 | 有现货 |
|
| 50MG | ￥9963 | 有现货 |
|
| 100MG | ￥13527 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称Etalocib
-
注意事项本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
-
产品简述Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase.
-
产品描述Etalocib is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities.
-
同义词LY293111; VML295
-
通路Apoptosis
-
靶点Apoptosis
-
受体Apoptosis;LTB4
-
研究领域——
-
适应症——
化学信息
-
CAS Number161172-51-6
-
分子量544.6
-
分子式C33H33FO6
-
纯度>98% (HPLC)
-
溶解度DMSO:100 mg/mL (183.62 mM; Need ultrasonic)
-
SMILESO=C(O)C1=CC=CC=C1OC2=CC=CC(OCCCOC3=C(CC)C=C(C4=CC=C(F)C=C4)C(O)=C3)=C2CCC
-
化学全称——
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.P Marder, et al. Blockade of Human Neutrophil Activation by 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- Hydroxyphenoxy]propoxy]phenoxy]benzoic Acid (LY293111), a Novel Leukotriene B4 Receptor Antagonist. Biochem Pharmacol. 1995 May 26;49(11):1683-90.
产品手册
关联产品
-
Lupiwighteone
Lupiwighteone has anti-angiogenesis potential, it also has anticancer and cancer preventive effects on SH-SY5Y cells.
-
Dihydrolycorine
Dihydrolycorine-HCL(DL) shows hypotensive effects, it can block alpha 1-adrenoceptors.
-
VTP50469
VTP50469 is a highly selective and orally active inhibitor of Menin-MLL interaction( Ki: 104 pM) and has potently anti-leukemia activity.
